API clinical trial dataset

The dataset includes immune readouts for API trial assessing the impact of antimicrobial treatments on penile ex vivo HIV susceptibility and immunology. This phase 1/2 clinical trial randomized HIV-uninfected Ugandan men (n=125) to either oral tinidazole, topical metronidazole, topical clindamycin or topical hydrogen peroxide to define impact on ex vivo foreskin HIV susceptibility, penile immunology and BASIC species density. Details are provided at ClinicalTrials.gov #NCT03412071. Groups within the dataset are as follows: 1=control, 2=oral tinidazole, 3=topical clindamycin, 4=topical hydrogen peroxide, 5=topical metronidazole.